rovadicitinib   Click here for help

GtoPdb Ligand ID: 12384

Synonyms: Anxu® (China) | example 5 [US10561657B2] | TQ-05105 | TQ05105
Approved drug Immunopharmacology Ligand
rovadicitinib is an approved drug
Compound class: Synthetic organic
Comment: This is the chemical structure for the INN rovadicitinib. The structure is claimed in patent US10561657B2, as a Janus kinase (JAK) inhibitor [4]. It later transpired that rovadicitinib (TQ05105) was a dual JAK1/2 and Rho kinase (ROCK) 1/2 inhibitor [5].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 4
Topological polar surface area 109.2
Molecular weight 321.17
XLogP 2.2
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES N#CC[C@@H](n1nc(c(c1)c1ncnc2c1cc[nH]2)N)C1CCCC1
Isomeric SMILES C1CCC(C1)[C@@H](CC#N)n1cc(c(n1)N)c1c2cc[nH]c2ncn1
InChI InChI=1S/C17H19N7/c18-7-5-14(11-3-1-2-4-11)24-9-13(16(19)23-24)15-12-6-8-20-17(12)22-10-21-15/h6,8-11,14H,1-5H2,(H2,19,23)(H,20,21,22)/t14-/m1/s1
InChI Key ZGENDZDSLYKCSI-CQSZACIVSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Blair HA. (2026)
Rovadicitinib: First Approval.
Drugs, [Epub ahead of print]. [PMID:42243570]
2. Hong M, Ding D, Zhang M, Gao S, Song L, Wu D, Lao S, Yu D, Chang C. (2025)
A first-in-class JAK/ROCK inhibitor, Rovadicitinib in patients with myelofibrosis who were refractory or relapsed or intolerant to Ruxolitinib: A single-arm, multicenter, open-label, phase Ib study.
Eur J Pharmacol, 1005: 178032. [PMID:40752760]
3. Ipek Y, Kilic B, Gunay UB, Eskazan AE. (2023)
Novel Janus-kinase (JAK) Inhibitors in Myelofibrosis.
Expert Opin Investig Drugs, 32 (10): 931-940. [PMID:37811861]
4. Li Z, Xiao D, Hu Y, Dai L, Duan X, Sun Y, Peng Y, Kong F, Luo H, Han Y et al.. (2022)
Pyrrolopyrimidine compound.
Patent number: US10561657B2. Assignee: Centaurus Biopharma Co Ltd Chia Tai Tianqing Pharmaceutical Group Co Ltd Lianyungang Runzhong Pharmaceutical Co Ltd. Priority date: 16/12/2014. Publication date: 18/02/2022.
5. Zhao YM, Luo Y, Shi JM, Wang SQ, Wang CK, Jiang EL, Liang C, Zhu XY, Zhang XJ, Meng FK et al.. (2025)
A first-in-class JAK/ROCK inhibitor, rovadicitinib, for glucocorticoid-refractory or -dependent chronic GVHD.
Blood, 145 (24): 2857-2872. [PMID:40009501]